Total third quarter revenues of $11.2 million, up 44% from the prior quarter, including $10.0 million from HEPZATO KIT™ (melphalan/Hepatic Delivery System) and $1.2 million from CHEMOSAT ®; Activated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback